• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝内胆管癌的分子和组织学特征及相关影像学特征

Molecular and Histological Profiles and Relevant Imaging Signatures of Intrahepatic Cholangiocarcinoma.

作者信息

Huang Huizhen, Chen Feng

机构信息

Department of Radiology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

出版信息

J Clin Transl Hepatol. 2025 Jun 28;13(6):504-515. doi: 10.14218/JCTH.2024.00410. Epub 2025 Apr 30.

DOI:10.14218/JCTH.2024.00410
PMID:40474889
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12134910/
Abstract

Intrahepatic cholangiocarcinoma (iCCA) is the second most prevalent primary liver cancer, characterized by insidious onset and high malignancy. Many patients are diagnosed at an inoperable stage, and the effectiveness of chemotherapy and radiotherapy remains limited. This study aimed to provide a comprehensive review of the histological classification, genetic alterations, molecular subtypes, and corresponding imaging signatures of iCCA, highlighting its heterogeneity and offering insights into targeted therapy and personalized treatment. The heterogeneity of iCCA poses significant challenges to both targeted therapy and immunotherapy, necessitating in-depth exploration at the molecular and subtyping levels. Investigating genetic variations, signaling pathway alterations, and molecular subtypes can aid in patient stratification. Stratifying iCCA patients allows for more precise treatment selection, ultimately improving survival outcomes. Imaging, as a non-invasive tool, holds substantial potential for predicting subtypes and molecular profiles. It is possible to infer histological and molecular features from imaging, or to interpret imaging signatures in light of known histological and molecular data. This integrative approach, combining external imaging with internal molecular insights, fosters a comprehensive understanding of iCCA's characteristics and enhances clinical management.

摘要

肝内胆管癌(iCCA)是第二常见的原发性肝癌,其特点是起病隐匿、恶性程度高。许多患者在无法手术的阶段被诊断出来,化疗和放疗的效果仍然有限。本研究旨在对iCCA的组织学分类、基因改变、分子亚型及相应的影像学特征进行全面综述,突出其异质性,并为靶向治疗和个性化治疗提供见解。iCCA的异质性对靶向治疗和免疫治疗都构成了重大挑战,需要在分子和亚型水平上进行深入探索。研究基因变异、信号通路改变和分子亚型有助于患者分层。对iCCA患者进行分层可以更精确地选择治疗方法,最终改善生存结果。影像学作为一种非侵入性工具,在预测亚型和分子特征方面具有巨大潜力。可以从影像学推断组织学和分子特征,或者根据已知的组织学和分子数据解释影像学特征。这种将外部影像学与内部分子见解相结合的综合方法,有助于全面了解iCCA的特征并加强临床管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d71/12134910/4e74da54e339/JCTH-13-504-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d71/12134910/d1ed1e19501d/JCTH-13-504-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d71/12134910/b5ea42338a1b/JCTH-13-504-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d71/12134910/559c407db5bf/JCTH-13-504-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d71/12134910/d6623fccfe85/JCTH-13-504-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d71/12134910/4e74da54e339/JCTH-13-504-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d71/12134910/d1ed1e19501d/JCTH-13-504-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d71/12134910/b5ea42338a1b/JCTH-13-504-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d71/12134910/559c407db5bf/JCTH-13-504-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d71/12134910/d6623fccfe85/JCTH-13-504-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d71/12134910/4e74da54e339/JCTH-13-504-g005.jpg

相似文献

1
Molecular and Histological Profiles and Relevant Imaging Signatures of Intrahepatic Cholangiocarcinoma.肝内胆管癌的分子和组织学特征及相关影像学特征
J Clin Transl Hepatol. 2025 Jun 28;13(6):504-515. doi: 10.14218/JCTH.2024.00410. Epub 2025 Apr 30.
2
Molecular and Pathological Heterogeneity of Synchronous Small and Large Duct Intrahepatic Cholangiocarcinoma-A Case Series.同步性小胆管和大胆管肝内胆管癌的分子与病理异质性——病例系列
Curr Oncol. 2025 Apr 27;32(5):255. doi: 10.3390/curroncol32050255.
3
Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma.肝内胆管癌的最新病理分类及分子特征
Front Med (Lausanne). 2022 Mar 31;9:857140. doi: 10.3389/fmed.2022.857140. eCollection 2022.
4
Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.肝内胆管癌:典型特征、罕见变异及存在争议的相关实体
Hum Pathol. 2023 Feb;132:197-207. doi: 10.1016/j.humpath.2022.06.001. Epub 2022 Jun 11.
5
Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma.肝内胆管癌病理学的最新进展
Cancers (Basel). 2024 Apr 17;16(8):1537. doi: 10.3390/cancers16081537.
6
Integrative analysis reveals different feature of intrahepatic cholangiocarcinoma subtypes.整合分析揭示了肝内胆管癌亚型的不同特征。
Liver Int. 2024 Sep;44(9):2477-2493. doi: 10.1111/liv.16015. Epub 2024 Jun 25.
7
Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.绘制肝内胆管癌中与可操作驱动因素相关的共突变模式。
J Hepatol. 2023 Mar;78(3):614-626. doi: 10.1016/j.jhep.2022.11.030. Epub 2022 Dec 15.
8
Heterogeneity of small duct- and large duct-type intrahepatic cholangiocarcinoma.小胆管型和大胆管型肝内胆管细胞癌的异质性。
Histopathology. 2024 May;84(6):1061-1067. doi: 10.1111/his.15162. Epub 2024 Feb 26.
9
Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers.肝内胆管癌全基因组 DNA 甲基化分析揭示具有不同生物学驱动因素的预后亚型。
Cancer Res. 2024 Jun 4;84(11):1747-1763. doi: 10.1158/0008-5472.CAN-23-3298.
10
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.肝内胆管癌结局的遗传决定因素。
Hepatology. 2021 Sep;74(3):1429-1444. doi: 10.1002/hep.31829.

本文引用的文献

1
Artificial intelligence-based MRI radiomics and radiogenomics in glioma.基于人工智能的脑胶质瘤 MRI 影像组学和放射组学。
Cancer Imaging. 2024 Mar 14;24(1):36. doi: 10.1186/s40644-024-00682-y.
2
Molecular Profile of Intrahepatic Cholangiocarcinoma.肝内胆管癌的分子特征。
Int J Mol Sci. 2023 Dec 29;25(1):461. doi: 10.3390/ijms25010461.
3
Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version).肝内胆管癌病理诊断专家共识(2022年版)
J Clin Transl Hepatol. 2023 Dec 28;11(7):1553-1564. doi: 10.14218/JCTH.2023.00118. Epub 2023 Jul 24.
4
Clinicopathological, etiological and molecular characteristics of intrahepatic cholangiocarcinoma subtypes classified by mucin production and immunohistochemical features.按黏蛋白产生和免疫组织化学特征分类的肝内胆管癌亚型的临床病理、病因学和分子特征。
Expert Rev Mol Diagn. 2023 May;23(5):445-456. doi: 10.1080/14737159.2023.2205588. Epub 2023 Apr 23.
5
Preoperative subcategorization based on magnetic resonance imaging in intrahepatic cholangiocarcinoma.术前基于磁共振成像的肝内胆管细胞癌的亚分类。
Cancer Imaging. 2023 Feb 13;23(1):15. doi: 10.1186/s40644-023-00533-2.
6
Impact of small duct- and large duct type on survival in patients with intrahepatic cholangiocarcinoma: Results from a German tertiary center.小胆管型和大胆管型对肝内胆管癌患者生存的影响:来自德国一家三级中心的结果。
Pathol Res Pract. 2022 Oct;238:154126. doi: 10.1016/j.prp.2022.154126. Epub 2022 Sep 16.
7
[Expert consensus on pathological diagnosis of intrahepatic cholangiocarcinoma (2022 version)].肝内胆管癌病理诊断专家共识(2022年版)
Zhonghua Bing Li Xue Za Zhi. 2022 Sep 8;51(9):819-827. doi: 10.3760/cma.j.cn112151-20220517-00423.
8
Subtype Classification of Intrahepatic Cholangiocarcinoma Using Liver MR Imaging Features and Its Prognostic Value.利用肝脏磁共振成像特征对肝内胆管癌进行亚型分类及其预后价值
Liver Cancer. 2022 Mar 30;11(3):233-246. doi: 10.1159/000521747. eCollection 2022 Jun.
9
Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities.多模块分析肝内胆管癌免疫亚群揭示了不同的治疗弱点。
J Immunother Cancer. 2022 Jul;10(7). doi: 10.1136/jitc-2022-004892.
10
Geospatial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma.空间免疫异质性反映了肝内胆管癌中不同的肿瘤免疫相互作用。
Cancer Discov. 2022 Oct 5;12(10):2350-2371. doi: 10.1158/2159-8290.CD-21-1640.